NCT04979780View on ClinicalTrials.gov

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

CompletedOBSERVATIONAL
Enrollment

3,708

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Treatment of Venous Thromboembolism in Cancer PatientsProphylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Retrospective cohort analysis using US Optum De-Identified EHR data.

DRUG

Low molecular weight heparin (LMWH)

Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)

DRUG

Direct Oral Anticoagulants (DOAC)

Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).

Trial Locations (1)

06093

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04979780 - Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort | Biotech Hunter | Biotech Hunter